Mild to moderate hand eczema. Atopic dermatitis
Conditions
Interventions
Intervention 1: Control group: The group receiving the cream is Momtazone 0.1% manufactured by Kish Medifarm Company in Iran. The cream is applied for 3 weeks every night and then for 2 weeks every ot
Sponsors
Traditional Medicine & Materia Medica Research center Shahid Beheshti university of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Men and women 18 years or older One or more eczema lesions in the palm or back area Mild to moderate plaques Patients who have not received topical, oral, or injectable medication for the treatment of eczema in the last week (emulsion use is permitted). Lack of infection or malignancy at the treatment site (no problem with closed wounds). Patient's consent to participate in the study
Exclusion criteria
Exclusion criteria: Under 18 years Pregnancy and lactation Eczema generalize Patients with other skin lesions Taking other topical medicines while participating in the research Patients taking immunosuppressive systemic drugs or biological drugs. Infection or skin malignancy at the treatment site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Atopic dermatitis disease intensity. Timepoint: At the beginning of the study and about 20 days after starting the topical cream (after treatment). Method of measurement: SCORAD Index form.;Duration of recovery. Timepoint: About 20 days after starting the topical cream (after treatment). Method of measurement: Patient Tracking and Evaluation with SCORAD and DLQI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of dermatology patient's life. Timepoint: At the beginning of the study and about 20 days after starting the topical cream (after treatment). Method of measurement: DLQI questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Ghadimi
Islamic Azad University
Outcome results
None listed